KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy-Reference-Cited by-同舟云学术

KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy

Published:2015-12-17 Issue:25 Volume:126 Page:2720-2723
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Yeung David T.¹²³^ORCID,Tang Carine²³,Vidovic Ljiljana²,White Deborah L.³⁴⁵,Branford Susan¹⁶⁷,Hughes Timothy P.²³⁵,Yong Agnes S.²³

Affiliation:

1. Department of Genetics and Molecular Pathology, Centre for Cancer Biology, and

2. Department of Haematology, SA Pathology, Adelaide, SA, Australia;

3. School of Medicine and

4. School of Paediatrics, University of Adelaide, Adelaide, SA, Australia;

5. Cancer Theme, South Australia Health and Medical Research Institute, Adelaide, SA, Australia;

6. School of Pharmacy and Medical Science, University of South Australia, Adelaide, SA, Australia; and

7. School of Molecular and Biomedical Science, University of Adelaide, Adelaide, SA, Australia

Abstract

Key Points KIR2DL5B is associated with poor molecular response and transformation-free survival in CML patients enrolled to the TIDEL-II study. KIR genotyping would select out high risk CML patients at baseline and allow better targeting of novel interventions.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/126/25/2720/1389918/2720.pdf

Reference25 articles.

1. Which TKI? An embarrassment of riches for chronic myeloid leukemia patients.;Hughes;Hematology Am Soc Hematol Educ Program,2013

2. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors.;Valiante;Immunity,1997

3. Pregnancy immunogenetics: NK cell education in the womb?;Parham;J Clin Invest,2010

4. Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR).;Purdy;Cancer Biol Ther,2009

5. Immunological aspects of cancer chemotherapy.;Zitvogel;Nat Rev Immunol,2008

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD302 predicts achievement of deep molecular response in patients with chronic myeloid leukemia treated with imatinib;Blood Neoplasia;2024-06

2. How to improve treatment‐free remission eligibility in chronic myeloid leukaemia?;British Journal of Haematology;2023-12-26

3. The Influence of KIR Gene Polymorphisms and KIR-ligand Binding on Outcomes in Hematologic Malignancies following Haploidentical Stem Cell Transplantation: A Comprehensive Review;Current Cancer Drug Targets;2023-12

4. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia;Leukemia;2023-10-04

5. Immunomodulatory Activity of the Tyrosine Kinase Inhibitor Dasatinib to Elicit NK Cytotoxicity against Cancer, HIV Infection and Aging;Pharmaceutics;2023-03-11